Transformational cell therapies for patients with pancreatic disease

Koligo is dedicated to advancing R&D and technologies to cure pancreatic disease.

The people, science and innovative mindset
to forever improve the lives of people we touch.

LEADERSHIP TEAM

Matthew Lehman,

Chief Executive Officer (Koligo Therapeutics Inc.) and Executive Director

Proven biotech & cell therapy executive
NASDAQ-listed Prima Biomed, CSE-listed M Pharmaceutical, private CRO SPRI Clinical Trials
Clinical research & manufacturing scale-up expertise
MS Columbia; BA Louisville

Balamurugan N. Appakalai, PhD,

Chief of Manufacturing (Koligo Therapeutics Inc.)

20+ years experience in islet cell isolation; 800 human & 600 pig pancreases
100+ peer reviewed articles & presentations
Director of Islet Cell Lab at Cardiovascular Innovation Institute, Louisville
Previous islet processing at Universities of Minnesota, Colorado in Denver, Pittsburgh

Mike Hughes, MD,

Chief Medical Officer (Koligo Therapeutics Inc.)

Director of Pancreas Transplantation, Assistant Professor of Surgery, Louisville
Initiated TP-IAT program in Louisville
20 clinical TP-IAT performed to date & negotiated reimbursement
MD Wake Forest, residency at Virginia Medical Center, fellowship at University of Minnesota

Stuart Williams, PhD,

Chief Technology Officer (Koligo Therapeutics Inc.) and Executive Director

Division chief, Bioficial Heart, Cardiovascular Innovation Institude
300+ publications & 16 issued US patents in cell & tissue engineering
Experienced academic-industry partner: founded three biotech companies
PhD cell biology University of Delaware, postdoc Yale School of Medicine

David Blanford,

Chief Financial Officer and Chief Operating Officer (Koligo Therapeutics Inc.)

Experienced financial executive for manufacturing and clinical companies
Managed private-equity investment, government grants, venture capital investment
BS Oral Roberts